Real-world evidence for geographic atrophy treatment — the Chinese patient population characteristics, GA lesion progression rates, genetic factors, and treatment response patterns informing clinical practice and commercial market development — represents an important market intelligence dimension, with the China Geographic Atrophy Market reflecting RWE as a commercially valuable market information asset.

Chinese AMD genetic research — the genome-wide association studies in Chinese populations identifying AMD-associated genetic variants (CFH, ARMS2, C3, CFB genes showing similar but not identical effect sizes versus European populations) — creating the Chinese-specific genetic understanding of AMD and GA susceptibility. The Chinese AMD genetic architecture informing risk stratification and potentially treatment response prediction.

GA progression rate variation — the clinical research documenting that Chinese patients may have different GA progression rates, lesion morphology characteristics, and visual impact patterns compared to clinical trial populations predominantly composed of European ancestry — creating the evidence gap requiring Chinese-specific natural history data. The OAKS/DERBY and GATHER trials enrolling predominantly non-Asian patients making Chinese-specific efficacy prediction uncertain.

Chinese retina academic center GA registry — the establishment of GA patient registries at Chinese academic retinal centers (Zhongshan Ophthalmic Center, PUMCH Eye Center, Ruijin Hospital Shanghai) creating the natural history data foundation for commercial market development. These registry programs creating the Chinese-specific clinical evidence that supports NMPA regulatory submissions and NHSA economic arguments.

Do you think Chinese GA patients will respond similarly to complement inhibitors as Western clinical trial populations, or are there biological and genetic differences requiring China-specific clinical evaluation?

FAQ

Are there differences in AMD/GA genetics between Chinese and European populations? Chinese versus European AMD genetics: shared risk loci: CFH, ARMS2/HTRA1, C3, CFB — present in both populations; differences: CFH Y402H (major European risk variant): lower frequency in Asian populations; ARMS2 rs10490924: comparable or higher frequency in Asians; C3 and complement pathway variants: similar overall; Asian-specific variants: additional Asian-specific AMD risk variants identified (CFI, C9, among others); clinical implications: GA genetic risk profile differs; potentially different complement pathway activation patterns; potential implications for complement inhibitor response; evidence: limited head-to-head comparison data for complement inhibitor response in Asian versus European patients; NMPA likely to require Chinese clinical data for GA treatment approval.

What GA natural history data exists for Chinese patients? Chinese GA natural history: limited systematic data; available data: retrospective analyses from Chinese retina referral centers; Zhongshan Ophthalmic Center published AMD registry data; challenge: GA diagnosis under-recognized historically; prospective registries: being established at major academic centers; observations: mean lesion growth rate approximately two to three mm² per year (consistent with global data); fovea-sparing versus fovea-involving patterns similar distribution; genetic risk factor distribution differs from European populations; practical implications: Chinese-specific natural history data important for NHSA pharmacoeconomic modeling; commercial companies expected to establish Chinese patient registries as part of NMPA registration strategy.

#ChinaGeographicAtrophy #ChinaAMDgenetics #RWEchina #ChineseGAprogression #GAresearch #ChinaRetinalRegistry